Skip to main content

#Ebola Virus Disease in the #DRC - External #Situation #Report 03 - September 28 '25 (#WHO, summary)

Image
By G.M.

 


Date of issue: 30 September 2025

Data as reported by: 28 September 2025


{Summary}

The Ebola virus disease outbreak in the Democratic Republic of the Congo continues, with signs of a notable decline in transmission. 

Since our last update (Situation Report #2), a total of seven new cases have been reported, comprising six confirmed and one probable cases (retrospectively validated). 

The new cases were detected across three health areas within Bulape Health Zone, namely, Bulape (n=4), Mpianga (n=2), and Dikolo (n=1). 

During the same reporting period, seven deaths occurred among newly identified and previously hospitalized cases. The reported deaths were distributed across Dikolo (n=3), Bulape (n=2), Mpianga (n=1), and Bulape Communitaire (n=1) health areas.

As of 28 September 2025, a total of 64 cases (53 confirmed and 11 probable), including 42 deaths (31 confirmed, 11 probable), have been reported from Bulape Health Zone, Kasai Province, Democratic Republic of the Congo. 

The overall case fatality ratio (CFR) is 65.6%. 

Cumulatively, five confirmed cases have been reported among healthcare workers, including three deaths. 

The outbreak remains confined to six affected health areas out of the 21 that make up Bulape Health Zone.

Cases to date range in age from 0 (newborn) to 65 years. 

Since the onset of the outbreak, the majority of cases have been reported among females (57.8%, n=37), children aged 0–9 years (25.0%, n=16), and individuals aged 20–29 years (23.4%, n=15). 

Mortality has also been concentrated among these groups, with females accounting for over half of the reported deaths (57.1%, n=24) and children under 10 years representing 31.0% of deaths (n=13). 

The CFR is slightly higher among males (66.7%) compared to females (64.9%). 

In the past two weeks, fewer cases (n = 2) have been reported among children (0-9 years old). 

A decreasing CFR trend has been observed over time with improvement in surveillance (early case detection and isolation) and the quality of case management (prompt and high-quality treatment).

As of 28 September 2025, a total of 1 787 contacts were under follow-up, with 1 735 (97.1%) seen in the last 24 hours. 

Nine (9) cases were successfully treated and discharged following recovery while 13 are currently in treatment as of 28 September 2025.

(...)

Source: ReliefWeb, https://reliefweb.int/attachments/de19e29d-1f89-4ad2-a086-e9afcdce91cc/DRC_EVD_External_Sitrep_28Sept2025.pdf

____

Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »